- Home
- ISRL vs HOWL Comparison
ISRL vs HOWL Comparison
Compare ISRL & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- HOWL
- Stock Information
- Founded
- ISRL 2021
- HOWL 2017
- Country
- ISRL United States
- HOWL United States
- Employees
- ISRL N/A
- HOWL N/A
- Industry
- ISRL Blank Checks
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- HOWL Health Care
- Exchange
- ISRL Nasdaq
- HOWL Nasdaq
- Market Cap
- ISRL 79.7M
- HOWL 64.5M
- IPO Year
- ISRL 2023
- HOWL 2021
- Fundamental
- Price
- ISRL $12.63
- HOWL $1.43
- Analyst Decision
- ISRL
- HOWL Strong Buy
- Analyst Count
- ISRL 0
- HOWL 5
- Target Price
- ISRL N/A
- HOWL $7.20
- AVG Volume (30 Days)
- ISRL 2.1K
- HOWL 147.5K
- Earning Date
- ISRL 01-01-0001
- HOWL 11-06-2025
- Dividend Yield
- ISRL N/A
- HOWL N/A
- EPS Growth
- ISRL N/A
- HOWL N/A
- EPS
- ISRL 0.14
- HOWL N/A
- Revenue
- ISRL N/A
- HOWL N/A
- Revenue This Year
- ISRL N/A
- HOWL N/A
- Revenue Next Year
- ISRL N/A
- HOWL N/A
- P/E Ratio
- ISRL $93.55
- HOWL N/A
- Revenue Growth
- ISRL N/A
- HOWL N/A
- 52 Week Low
- ISRL $11.14
- HOWL $0.60
- 52 Week High
- ISRL $14.00
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- ISRL 52.16
- HOWL 61.71
- Support Level
- ISRL $11.99
- HOWL $1.29
- Resistance Level
- ISRL $12.70
- HOWL $1.49
- Average True Range (ATR)
- ISRL 0.13
- HOWL 0.07
- MACD
- ISRL 0.01
- HOWL 0.01
- Stochastic Oscillator
- ISRL 90.14
- HOWL 70.00
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.